Soluble F proteins exacerbate pulmonary histopathology after vaccination upon respiratory syncytial virus challenge but not when presented on virus-like particles

被引：22

作者：

Lee, Youri ^{[1
,2
]}

Lee, Young-Tae ^{[1
]}

Ko, Eun-Ju ^{[1
]}

Kim, Ki-Hye ^{[1
]}

Hwang, Hye Suk ^{[1
]}

Park, Soojin ^{[1
]}

Kwon, Young-Man ^{[1
]}

Kang, Sang Moo ^{[1
,2
]}

机构：

[1] Georgia State Univ, Inst Biomed Sci, Ctr Inflammat Immun & Infect, Atlanta, GA 30303 USA

[2] Georgia State Univ, Dept Biol, Inst Biomed Sci, Atlanta, GA USA

来源：

HUMAN VACCINES & IMMUNOTHERAPEUTICS | 2017年 / 13卷 / 11期

关键词：

enhanced disease; F protein; respiratory syncytial virus; safety; virus-like particle; IMMUNE-RESPONSES; COTTON RATS; CPG OLIGODEOXYNUCLEOTIDE; CONFERS PROTECTION; FUSION PROTEIN; GLYCOPROTEIN; RSV; DISEASE; MICE; IMMUNIZATION;

D O I：

10.1080/21645515.2017.1362514

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Respiratory syncytial virus (RSV) fusion (F) protein is suggested to be a protective vaccine target although its efficacy and safety concerns remain not well understood. We investigated immunogenicity, efficacy, and safety of F proteins in a soluble form or on virus-like particle (F-VLP). F VLP preferentially elicited IgG2a antibody and T helper type 1 (Th1) immune responses whereas F protein induced IgG1 isotype and Th2 responses. Despite lung viral clearance after prime or prime-boost and then RSV challenge, F protein immune mice displayed weight loss and lung histopathology and high mucus production and eosinophils. In contrast, prime or prime-boost vaccination of F VLP induced effective protection, prevented infiltration of eosinophils and vaccine- enhanced disease after challenge. This study provides insight into developing an effective and safe RSV vaccine candidate.

引用

页码：2594 / 2605

页数：12

共 43 条

[1] Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants [J].

Boeckh, M ;

Berrey, MM ;

Bowden, RA ;

Crawford, SW ;

Balsley, J ;

Corey, L .

JOURNAL OF INFECTIOUS DISEASES, 2001, 184 (03) :350-354

[2] FIELD EVALUATION OF A RESPIRATORY SYNCYTIAL VIRUS VACCINE AND A TRIVALENT PARAINFLUENZA VIRUS VACCINE IN A PEDIATRIC POPULATION [J].

CHIN, J ;

MAGOFFIN, RL ;

SHEARER, LA ;

SCHIEBLE, JH ;

LENNETTE, EH .

AMERICAN JOURNAL OF EPIDEMIOLOGY, 1969, 89 (04) :449-+

[3] COTTON RATS PREVIOUSLY IMMUNIZED WITH A CHIMERIC RSV FG GLYCOPROTEIN DEVELOP ENHANCED PULMONARY PATHOLOGY WHEN INFECTED WITH RSV, A PHENOMENON NOT ENCOUNTERED FOLLOWING IMMUNIZATION WITH VACCINIA RSV RECOMBINANTS OR RSV [J].

CONNORS, M ;

COLLINS, PL ;

FIRESTONE, CY ;

SOTNIKOV, AV ;

WAITZE, A ;

DAVIS, AR ;

HUNG, PP ;

CHANOCK, RM ;

MURPHY, BR .

VACCINE, 1992, 10 (07) :475-484

[4] A Role for the Chemokine RANTES in Regulating CD8 T Cell Responses during Chronic Viral Infection [J].

Crawford, Alison ;

Angelosanto, Jill Marie ;

Nadwodny, Kim Lynn ;

Blackburn, Shawn D. ;

Wherry, E. John .

PLOS PATHOGENS, 2011, 7 (07)

[5] Cotton rat immune responses to virus-like particles containing the pre-fusion form of respiratory syncytial virus fusion protein [J].

Cullen, Lori McGinnes ;

Blanco, Jorge C. G. ;

Morrison, Trudy G. .

JOURNAL OF TRANSLATIONAL MEDICINE, 2015, 13

[6] Monocyte Chemoattractant Protein-1 (MCP-1): An Overview [J].

Deshmane, Satish L. ;

Kremlev, Sergey ;

Amini, Shohreh ;

Sawaya, Bassel E. .

JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2009, 29 (06) :313-326

[7] Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease [J].

Florencia Delgado, Maria ;

Coviello, Silvina ;

Clara Monsalvo, A. ;

Melendi, Guillermina A. ;

Zea Hernandez, Johanna ;

Batalle, Juan P. ;

Diaz, Leandro ;

Trento, Alfonsina ;

Chang, Herng-Yu ;

Mitzner, Wayne ;

Ravetch, Jeffrey ;

Melero, Jose A. ;

Irusta, Pablo M. ;

Polack, Fernando P. .

NATURE MEDICINE, 2009, 15 (01) :34-41

[8] RESPIRATORY VIRUS IMMUNIZATION .I. A FIELD TRIAL OF 2 INACTIVATED RESPIRATORY VIRUS VACCINES - AN AQUEOUS TRIVALENT PARAINFLUENZA VIRUS VACCINE AND AN ALUM-PRECIPITATED RESPIRATORY SYNCYTIAL VIRUS VACCINE [J].

FULGINITI, VA ;

ELLER, JJ ;

SIEBER, OF ;

JOYNER, JW ;

MINAMITANI, M ;

MEIKLEJOHN, G .

AMERICAN JOURNAL OF EPIDEMIOLOGY, 1969, 89 (04) :435-+

[9] Enhanced immune responses and protection by vaccination with respiratory syncytial virus fusion protein formulated with CpG oligodeoxynucleotide and innate defense regulator peptide in polyphosphazene microparticles [J].

Garlapati, S. ;

Garg, R. ;

Brownlie, R. ;

Latimer, L. ;

Simko, E. ;

Hancock, R. E. W. ;

Babiuk, L. A. ;

Gerdts, V. ;

Potter, A. ;

Littel-van den Hurk, S. van Drunen .

VACCINE, 2012, 30 (35) :5206-5214

[10] Safety and immunogenicity of novel respiratory syncytial virus (RSV) vaccines based on the RSV viral proteins F, N and M2-1 encoded by simian adenovirus (PanAd3-RSV) and MVA (MVA-RSV); protocol for an open-label, dose-escalation, single-centre, phase 1 clinical trial in healthy adults [J].

Green, C. A. ;

Scarselli, E. ;

Voysey, M. ;

Capone, S. ;

Vitelli, A. ;

Nicosia, A. ;

Cortese, R. ;

Thompson, A. J. ;

Sande, C. S. ;

de Lara, Catherine ;

Klenerman, P. ;

Pollard, A. J. .

BMJ OPEN, 2015, 5 (10)

← 1 2 3 4 5 →